Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guidelines are a collection of consensus statements developed by experts in the treatment of specific types of cancer. Each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients.
In response to the ever-growing demand for expert advice on the optimal use of immunotherapy treatments, our Cancer Immunotherapy Guidelines Task Forces have developed consensus statements for genitourinary malignancies (renal and prostate carcinoma) and hematologic malignancies (multiple myeloma, lymphoma and acute leukemia). An update of the melanoma consensus statement and new guidelines for bladder and lung cancers are also underway.
Click here for a complete listing of the guidelines and links to view.
SITC is the first and only organization dedicated to cancer immunotherapy to be accepted as a formal member of the Commission on Cancer (CoC), a program of the American College of Surgeons.
The CoC is the nation’s leading accreditation body for cancer care and has established a strong partnership approach to defining and measuring quality as it relates to managing patients with cancer. Today, more than 80 percent of Americans with cancer will seek treatment at a CoC accredited facility.
SITC represents leaders of the field of cancer immunotherapy, to help establish and implement immunotherapy at CoC-accredited institutions and develop mechanisms for collecting data and educating healthcare providers on the optimal way to deliver immunotherapy. SITC Immediate Past President, Howard Kaufman, MD, FACS, of the Rutgers Cancer Institute of New Jersey, serves as SITC’s official liaison to the Commission.
SITC has been a key collaborator in the development of the Foundation for the Accreditation of Cellular Therapy (FACT) Standards for Immune Effector Cell Administration.Marcela Maus, MD, PhD of Harvard Medical School serves as SITC’s official liaison to the FACT CAR-T Cell Task Force.
SITC provided formal comments to the FACT draft of the 1st edition FACT Standards for Immune Effector Cell Administration. These standards are intended to promote quality in the administration of immune effector cells and will be incorporated into a voluntary FACT accreditation in this field.
Click here to download "Standards for Immune Effector Cell Administration".
Immunotherapy@Brisbane 2017 Register online before Friday April 21! Final Program Released
EMBO KEYNOTE LECTURE Professor Sir Marc Feldmann Kennedy Institute of Rheumatology, University of Oxford, UK KEY SPEAKER Professor Shimon ...
This message was posted by a user wishing to remain anonymous Another Great Pittsburgher Dies - Philanthropist Henry Hillman led the renaissance of Pittsburgh's rebirth, a benefactor of the Hillman Cancer Center, an NCI Designated Cancer Center. http://www.post-gazette.com/local/city/2017/04/14/Philanthropist-Henry-Hillman-dies/stories/201704140181
Published April 11, 2017, in JAMA are the United States Preventative Services Task Force new recommendations for the surveillance of Prostate Cancer. The USPSTF recommends that the decision to have a DRE and prostate screening with PSA should be up ...
Immunotherapy@Brisbane 2017 Register online before Friday April 21! Leading International Speakers
EMBO KEYNOTE LECTURE Professor Sir Marc Feldmann Kennedy Institute of Rheumatology, University of Oxford, UK KEY SPEAKER ...
Greetings SITC researchers: Prostate cancer is not very responsive to immune checkpoint blockade (ICB). Why is that? A "Nature" journal paper just out (3/29/17 currently online only) appears to add a "secret sauce" that combines Immune checkpoint blockade ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org